For better harmonization of NPM1-mutated AML data, log reduction of MRD should be the preferred choice for reporting, as multiple studies have shown that MRD kinetics are reliable prognostic indicators of the outcome, but not absolute MRD levels [62,64]. The gene discussed is NPM1; the disease is acute myeloid leukemia.